权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Master regulators of unexplained variation in disease risk

疾病风险无法解释的变异的主要调节因素

基本信息

批准号：
10492766
负责人：
JOSEPH H. NADEAU
金额：
$ 191.92万
依托单位：
VAN ANDEL RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-22 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10492766
关键词：
Address Animal Model Architecture Area Atlases Biological Biological Models Biomedical Research Catalogs Chromosomes Communities Complex Data Databases Development Diagnosis Diagnostic Dimensions Disease Diseases in Twins Elderly Environment Epigenetic Process Etiology Gene Activation Gene Expression Gene Silencing Genetic Genome Genotype Heterogeneity Human Human Genetics Inbreeding Individual International Knowledge Lead Link Mainstreaming Measures Medicine Metabolic Methods Molecular Monozygotic twins Mouse Strains Mus Neurologic Organism Outcome Persons Phenotype Phylogenetic Analysis Physiological Population Analysis Precision Medicine Initiative Process Property Protocols documentation Quantitative Trait Loci Regulator Genes Reporting Science Seminal Standardization Surveys Testing Therapeutic Intervention Variant Vertebrates Work biological systems cohort data resource disease heterogeneity disorder risk driving force genome-wide human disease innovation insight interest non-Gaussian model non-genetic precision medicine trait

项目摘要

PROJECT SUMMARY Precision medicine requires an understanding of the origins and molecular control over complex traits and disease. The field is largely driven by human genetics, which adheres to a 1918 dogma that phenotype is determined solely by genetics and the environment. Yet, evidence from monozygotic twins and isogenic animal models indicate that up to 50% of phenotypic variation across diverse physiological traits and diseases cannot be explained by genetics or environment – there is something `more' that is unique to each individual, and that cannot be determined by analyzing population-level mean effects. These findings also indicate that even if we did have `complete' genetic and environmental knowledge, a substantial portion of disease heterogeneity would remain unaccounted for. The operating hypothesis for this project is that a substantial fraction of unexplained disease heterogeneity reflects inherently probabilistic properties of the biological system that lead to fixed, deterministic, real biological variation. There is compelling evidence for an evolved molecular circuitry that controls phenotypic variability as a quantitative trait. Thus, understanding variability as a quantitative trait is essential to understanding the etiology of phenotypic diversity (in general) and an individual's disease potential (in particular). Here, we will begin to finally answer the precision medicine questions of: what is the normal or expected disease potential for me? And, what are the origins and regulatory controls of non-genetic, non- environmental phenotypic and disease variability in humans? The first steps towards addressing these questions and identifying mechanisms through which probabilistic processes lead to disease heterogeneity is to create a catalogue of putative variance regulators and genes; a phenotypic, epigenetic, and cellular variance atlas charting the landscape of probabilistic variation in an isogenic model system (mice); and, to demonstrate that the regulatory architecture of variance control is conserved between mouse and humans. If it is true that a significant portion of unexplained disease heterogeneity is due to the molecular control of variability itself, then we will have uncovered an entirely new area of disease etiology that can be harnessed by the community to develop fundamentally new predictive, diagnostic, and therapeutic interventions, irrespective of the disease of interest.

项目总结